Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:58:09.830Z.
Calculation as of: 2026-10-06T18:58:09.830Z.
Quote observation: 2026-10-06T18:42:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9eb175beb73ea6d5bc2b5d4e57ff3726ad64c6dbf03440990cee379981bf6545
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Psyence Biomedical Ltd.
Market Cap
$96215.00
Price/OCF Ratio
N/A
Market Cap
$30263.00
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Psyence Biomedical Ltd. (PBM) | $96215.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108771.00 | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30263.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6001.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $352721.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
